Corona Remedies Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹441 Cr +22.2% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
CR

Corona Remedies Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Corona Remedies Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹353Cr
+20.1% YoY
+3.2% QoQ
Net profit
₹45Cr
+45.2% YoY
+9.8% QoQ
Margin
18%
0 pp YoY
−6 pp QoQ
Price₹2,143
Market cap₹12.8K Cr
P/E60.6

The short version

Anticipated overall IPM growth for FY27 is about 10% to 10.3%, with volume growth expected at 1.5% to 2%; rest driven by price and new launches. CORONA Remedies Limited targets a revenue growth of 15% organically and 25% from the acquired portfolio in FY27.

From Corona Remedies Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Anticipated overall IPM growth for FY27 is about 10% to 10.3%, with volume growth expected at 1.5% to 2%; rest driven by price and new launches.
  • CORONA Remedies expects to outperform the market volume growth by about 3x to 4x through added medical representatives and restructuring of divisions, including launching new products like Wokadine.
  • Committed to 15% organic revenue growth domestically and 25% growth in the acquired portfolio, targeting 20%+ PAT growth in FY27.

2 more points from Corona Remedies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Corona Remedies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Expansion of manufacturing capabilities with the addition of a new 600-kg production line.
  • Commissioning of a dedicated hormone manufacturing plant expected to be operational in Q1 or Q2 of FY27.
  • Receipt of EAEU GMP certification enabling expansion into key Eurasian markets (Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan).
  • These investments aim to strengthen manufacturing backbone, improve scalability, and support growth in domestic and international business.

2 more points from Corona Remedies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Corona Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Corona Remedies Ltd said on order book & pipeline — free account, 30 seconds.

Corona Remedies Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Corona Remedies Ltd Q4 FY26 results — key figures

Corona Remedies Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue353294+20.1%342+3.2%
Operating profit (EBITDA)6254+14.8%83-25.3%
Operating margin18%18%0 pp24%-6 pp
Profit before tax5443+25.6%55-1.8%
Net profit (PAT)4531+45.2%41+9.8%
EPS (₹)7.375.12+43.9%6.74+9.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹441 Cr, net profit ₹60 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Corona Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Corona Remedies Ltd Q4 FY26 results?

Anticipated overall IPM growth for FY27 is about 10% to 10.3%, with volume growth expected at 1.5% to 2%; rest driven by price and new launches. CORONA Remedies Limited targets a revenue growth of 15% organically and 25% from the acquired portfolio in FY27.

What is Corona Remedies Ltd share price analysis?

Corona Remedies Ltd currently shows a neutral. The stock trades at a P/E of 60.6 with a market cap of ₹12,823 Cr. Investors should review the full earnings analysis for detailed insights.

Is Corona Remedies Ltd planning capital expenditure?

Expansion of manufacturing capabilities with the addition of a new 600-kg production line.

Keep Corona Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.